File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Non-aggressive therapy for chronic myeloid leukaemia in blastic transformation

TitleNon-aggressive therapy for chronic myeloid leukaemia in blastic transformation
Authors
Issue Date1992
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1992, v. 29 n. 4, p. 323-325 How to Cite?
AbstractA total of 40 patients presenting with chronic myeloid leukaemia in blastic transformation were treated with a non-aggressive chemotherapy regimen consisting of vincristine, cytosine arabinoside and thioguanine. Remissions were achieved by 3/10 (30%) patients displaying lymphoid transformation (remission duration, 2, 3, and 5 months, respectively) and by 5/30 (17%) subjects exhibiting myeloid changes (duration 2+, 4, 4, 5 and 7 months, respectively). Myelosuppression was the major toxicity and non-haematological toxicities were mild and acceptable. The median survival of patients exhibiting lymphoid and myeloid blastic transformation as measured from the time of transformation was 6 and 3 months, respectively, but the difference was not statistically significant. Three subjects displaying lymphoid transformation and five showing myeloid changes survived for >12 months after the time of transformation.
Persistent Identifierhttp://hdl.handle.net/10722/161923
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorChiu, Een_US
dc.contributor.authorTodd, Den_US
dc.date.accessioned2012-09-05T05:16:03Z-
dc.date.available2012-09-05T05:16:03Z-
dc.date.issued1992en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1992, v. 29 n. 4, p. 323-325en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161923-
dc.description.abstractA total of 40 patients presenting with chronic myeloid leukaemia in blastic transformation were treated with a non-aggressive chemotherapy regimen consisting of vincristine, cytosine arabinoside and thioguanine. Remissions were achieved by 3/10 (30%) patients displaying lymphoid transformation (remission duration, 2, 3, and 5 months, respectively) and by 5/30 (17%) subjects exhibiting myeloid changes (duration 2+, 4, 4, 5 and 7 months, respectively). Myelosuppression was the major toxicity and non-haematological toxicities were mild and acceptable. The median survival of patients exhibiting lymphoid and myeloid blastic transformation as measured from the time of transformation was 6 and 3 months, respectively, but the difference was not statistically significant. Three subjects displaying lymphoid transformation and five showing myeloid changes survived for >12 months after the time of transformation.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshBlast Crisis - Drug Therapy - Mortalityen_US
dc.subject.meshChilden_US
dc.subject.meshCytarabine - Administration & Dosageen_US
dc.subject.meshDaunorubicin - Administration & Dosageen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHydroxyurea - Administration & Dosageen_US
dc.subject.meshLeukemia - Drug Therapy - Mortalityen_US
dc.subject.meshLeukemia, Myeloid, Chronic-Phase - Drug Therapy - Mortality - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMethotrexate - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshThioguanine - Administration & Dosageen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleNon-aggressive therapy for chronic myeloid leukaemia in blastic transformationen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF00685953-
dc.identifier.pmid1537081-
dc.identifier.scopuseid_2-s2.0-0026530876en_US
dc.identifier.volume29en_US
dc.identifier.issue4en_US
dc.identifier.spage323en_US
dc.identifier.epage325en_US
dc.identifier.isiWOS:A1992HE30000013-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChiu, E=24827833600en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats